MUNICH, Germany and WILMINGTON, DE, U.S., May 28, 2025 / Biotech Newswire / --

德国慕尼黑和美国特拉华州威尔明顿，2025年5月28日 /生物技术新闻社/ --

DEBRA Research GmbH

德布拉研究有限公司

, a global non-profit organization dedicated to advancing research and drug development for those affected by Epidermolysis Bullosa (EB), and

，一个致力于为受表皮松解症（EB）影响的群体推进研究和药物开发的全球非营利组织，以及

Dermaliq Therapeutics, Inc.

德玛利克治疗学公司

, a clinical-stage dermatology innovator company developing next-generation topical therapies, today announced a strategic, non-exclusive collaboration to advance cutaneous drug delivery into the skin for EB. Initially, the partners will focus on improving wound-healing and anti-itch therapies, plus developing prophylactic therapies for people suffering from EB.

，一家临床阶段的皮肤病学创新公司，正在开发下一代局部治疗药物，今天宣布了一项战略性、非独家的合作，旨在推进针对EB的皮肤药物递送。最初，合作伙伴将专注于改善伤口愈合和止痒治疗，并为EB患者开发预防性疗法。

As part of the agreement, DEBRA Research has also made a strategic investment in Dermaliq..

作为协议的一部分，DEBRA Research 还对 Dermaliq 做出了战略投资。

EB is a group of rare and painful genetic skin disorders characterized by extremely fragile skin, leading to blisters and wounds from even minor friction or trauma. EB significantly affects the daily lives of people living with the condition and is associated with substantial morbidity and mortality over time due to chronic wounds, infections, and complications involving internal organs.

EB是一组罕见且痛苦的遗传性皮肤病，其特征是皮肤极其脆弱，即使受到轻微的摩擦或创伤也会导致水疱和伤口。EB会显著影响患者的生活质量，并且由于慢性伤口、感染以及涉及内部器官的并发症，随着时间的推移，会导致显著的发病和死亡风险。

It is caused by mutations in one or more genes that encode proteins responsible for maintaining the structural integrity of the skin. While there is currently no cure, novel treatments are being developed to manage symptoms, reduce pain, and improve quality of life..

它是由一个或多个编码负责维持皮肤结构完整性蛋白质的基因突变引起的。虽然目前尚无治愈方法，但正在开发新的治疗方法来控制症状、减轻疼痛并提高生活质量。

Dermaliq is set to transform therapeutic strategies for skin and wound management in EB. Leveraging its proprietary hyliQ® technology, the company enables targeted delivery of active compounds into the skin without mechanical interference to fragile or wounded tissue. Applied touchless, hyliQ® is designed specifically for conditions like EB, where the skin is exceptionally delicate and prone to blistering or damage from even minimal friction.

Dermaliq 即将变革EB皮肤和伤口管理的治疗策略。公司利用其专有的 hyliQ® 技术，能够在不机械干扰脆弱或受损组织的情况下，将活性化合物精准递送至皮肤。hyliQ® 采用无接触应用方式，专为像EB这样皮肤极其娇嫩、即使轻微摩擦也容易起泡或受损的情况设计。

This innovative approach offers critical therapeutic benefits for patients by delivering effective treatments while preserving the integrity of compromised skin..

这种创新方法通过提供有效治疗的同时保持受损皮肤的完整性，为患者提供了关键的治疗益处。

“This partnership aligns closely with our mission to accelerate the development of effective, high-impact therapies for people living with EB,”

“该合作与我们的使命紧密契合，即加速为患有EB的人群开发有效且具有高影响力的疗法。”

said Dr Christoph Coch MD, Managing Director at DEBRA Research.

DEBRA Research董事总经理克里斯托夫·科赫医学博士说。

“Dermaliq’s unique technology platform and clinical pipeline offer a promising approach to overcome the limitations of existing topical treatments, particularly for application on the damaged and fragile skin characteristic of EB. We believe this collaboration will play a pivotal role in advancing transformative therapies and improving both medical outcomes and quality of life for those affected by this devastating condition.”.

“Dermaliq的独特技术平台和临床管线为克服现有局部治疗的局限性提供了一个有前景的方法，特别是对于表皮松解症（EB）特有的受损和脆弱皮肤的应用。我们相信，此次合作将在推进变革性疗法、改善受这一严重疾病影响患者的医疗效果和生活质量方面发挥关键作用。”

“We are excited to join forces with DEBRA Research to bring our technology to an area of urgent and unmet medical need,”

“我们很高兴与DEBRA研究合作，将我们的技术应用于一个迫切且未满足的医疗需求领域，”

said Frank Löscher, PhD, CEO of Dermaliq.

德玛利克公司首席执行官、博士弗兰克·勒舍尔表示。

“This partnership underscores our shared commitment to addressing the urgent needs of people living with this debilitating disorder. With its unique features and exceptional safety profile, hyliQ® is ideally suited for the touchless topical treatment of disease-affected and damaged skin. We look forward to the impact this collaboration can bring to the EB community and beyond.”.

“这一合作强调了我们共同致力于解决患有这种衰弱性疾病的患者的迫切需求。hyliQ®凭借其独特的特性和卓越的安全性，非常适合用于无接触的局部治疗受疾病影响和受损的皮肤。我们期待这次合作能为EB患者群体及更多人带来的影响。”

About

关于

DEBRA Research

德布拉研究

DEBRA Research is a non-profit organization dedicated to advancing treatments and cures for EB, a rare and life-limiting genetic condition. As the research arm of DEBRA Austria - a patient organization established in 1995 to support individuals living with EB – DEBRA Research collaborates globally with academia, biotech, pharma, patient organizations, and regulatory bodies to drive innovation.

DEBRA Research 是一家非营利组织，致力于推进对EB（一种罕见且危及生命的遗传病）的治疗和治愈方法。作为 DEBRA Austria 的研究部门——该患者组织成立于1995年，旨在支持EB患者——DEBRA Research 与全球的学术界、生物技术公司、制药企业、患者组织及监管机构合作，推动创新发展。

DEBRA Research focuses on translational research and clinical development to address the unmet needs of people living with EB. Its goal is to accelerate the discovery and development of treatments improving quality of life, while striving for a future where EB is curable – a “world without EB.”.

DEBRA Research 专注于转化研究和临床开发，以满足 EB 患者未被满足的需求。其目标是加速发现和开发改善生活质量的治疗方法，同时努力实现 EB 可治愈的未来——一个“没有 EB 的世界”。

For more information, please visit

更多信息，请访问

www.debra-research.org

www.debra-research.org

and follow us on

并关注我们

LinkedIn

领英

.

。

About

关于

Dermaliq Therapeutics

德玛利克治疗学

Dermaliq Therapeutics, Inc. is uniquely positioned to revolutionize topical dermatology. With our proprietary hyliQ® technology platform, we are breaking through traditional delivery barriers, enabling for the first time the targeted absorption into skin structures with unmatched bioavailability and cutaneous tolerability.

Dermaliq Therapeutics, Inc. 凭借其独有的 hyliQ® 技术平台，彻底革新了局部皮肤病学领域。我们突破了传统的递送屏障，首次实现了针对皮肤结构的靶向吸收，具备无与伦比的生物利用度和皮肤耐受性。

This breakthrough paves the way for first-in-class and best-in-class topical treatments with broad application across dermatology and rare disease indications, offering substantial opportunities for long-term growth and value creation..

这一突破为跨皮肤病学和罕见病适应症的首创和最佳局部治疗铺平了道路，为长期增长和价值创造提供了巨大的机会。

Dermaliq’s pipeline includes clinical stage assets in androgenetic alopecia, alopecia areata and wound healing.

德玛利克的管道包括处于临床阶段的雄激素性脱发、斑秃和伤口愈合资产。

Contacts

联系人

DEBRA Research GmbH

德布拉研究有限公司

Dr Christoph Coch, Managing Director

克里斯托夫·科赫博士，总经理

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到防垃圾邮件机器人的保护。您需要启用 JavaScript 才能查看它。

Media Inquiries: MC Services

媒体咨询：MC服务

Dr Cora Kaiser, Dr Johanna Kobler

科拉·凯撒博士，约翰娜·科布勒博士

+49 89 210 2280

+49 89 210 2280

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Dermaliq Therapeutics, Inc.

德玛利克治疗学公司

Dr Frank Löscher, CEO

弗兰克·勒歇尔博士，首席执行官

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Keywords: International Cooperation; Epidermolysis Bullosa; Drug Delivery Systems; Skin; Skin Abnormalities; Wound Healing; Drug Development; DEBRA Research; Dermaliq Therapeutics; strategic collaboration; cutaneous drug delivery; topical treatments; itch relief; hyliQ® technology platform; touchless delivery; blisters; chronic wounds; active compound delivery; DEBRA Austria; topical dermatology.

关键词：国际合作；表皮松解症；药物递送系统；皮肤；皮肤异常；伤口愈合；药物开发；DEBRA研究；Dermaliq治疗；战略协作；皮肤药物递送；局部治疗；止痒；hyliQ®技术平台；无接触递送；水疱；慢性伤口；活性化合物递送；DEBRA奥地利；局部皮肤病学。

Source: Biotech Newswire

来源：生物技术新闻专线